In 2023, Singapore dominated the ranking of the world's health and health systems, followed by Japan and South Korea. The health index score is calculated by evaluating various indicators that assess the health of the population, and access to the services required to sustain good health, including health outcomes, health systems, sickness and risk factors, and mortality rates. The health and health system index score of the top ten countries with the best healthcare system in the world ranged between 82 and 86.9, measured on a scale of zero to 100.

Global Health Security Index  Numerous health and health system indexes have been developed to assess various attributes and aspects of a nation's healthcare system. One such measure is the Global Health Security (GHS) index. This index evaluates the ability of 195 nations to identify, assess, and mitigate biological hazards in addition to political and socioeconomic concerns, the quality of their healthcare systems, and their compliance with international finance and standards. In 2021, the United States was ranked at the top of the GHS index, but due to multiple reasons, the U.S. government failed to effectively manage the COVID-19 pandemic. The GHS Index evaluates capability and identifies preparation gaps; nevertheless, it cannot predict a nation's resource allocation in case of a public health emergency.

Universal Health Coverage Index  Another health index that is used globally by the members of the United Nations (UN) is the universal health care (UHC) service coverage index. The UHC index monitors the country's progress related to the sustainable developmental goal (SDG) number three. The UHC service coverage index tracks 14 indicators related to reproductive, maternal, newborn, and child health, infectious diseases, non-communicable diseases, service capacity, and access to care. The main target of universal health coverage is to ensure that no one is denied access to essential medical services due to financial hardships. In 2021, the UHC index scores ranged from as low as 21 to a high score of 91 across 194 countries. 

In 2023, the health care system in Finland ranked first with a care index score of ****, followed by Belgium and Japan. Care systems index score is measured using multiple indicators from various public databases, it evaluates the capacity of a health system to treat and cure diseases and illnesses, once it is detected in the population This statistic shows the care systems ranking of countries worldwide in 2023, by their index score.

According to a 2021 health care systems ranking among selected high-income countries, the United States came last in the overall ranking of its health care system performance. The overall ranking was based on five performance categories, including access to care, care process, administrative efficiency, equity, and health care outcomes. For the category administrative efficiency, which measures the amount of paperwork for providers and patients in the health system, the U.S. was ranked last, while Norway took first place. This could be because the health system in the U.S. is a multi-payer system, while Norway has a single-payer system, which most likely simplifies documentation and billing tasks. This statistic present the health care administrative efficiency rankings of the United States' health care system compared to ten other high-income countries in 2021.

The healthcare ranking reflects the quality of health care and access to health services in different countries. The assessment includes various factors such as life expectancy, access to medical services, healthcare funding, and technologies.

In 2023, Norway ranked first with a health index score of 83, followed by Iceland and Sweden. The health index score is calculated by evaluating various indicators that assess the health of the population, and access to the services required to sustain good health, including health outcomes, health systems, sickness and risk factors, and mortality rates. The statistic shows the health and health systems ranking of European countries in 2023, by their health index score.

BackgroundssssHealth system performance is a multifaceted concept that encompasses various dimensions of a nation’s healthcare infrastructure. This study aims to assess and rank the performance of health systems across different regions of the world.MethodologyWe employed the Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS) method in 2023 to evaluate and rank the health system performance of 31 countries across six geographical regions. Our evaluation included six general categories and twelve indicators related to health, finance, and the COVID-19 pandemic. The final weights for these indicators were determined using the Three-scale method and the Entropy-weighting method. Additionally, we categorized health system performance into three groups: high, moderate, and low. Hierarchical clustering of health system performance scores was conducted using SPSS software (version 26).ResultsLuxembourg emerged as the only high-performing health system, while Qatar and the Netherlands fell into the moderate-performance group. Other countries exhibited low-performing health systems. Notably, within the low-performance group, the United States of America, Australia, Singapore, Canada, England, and Germany achieved relatively better rankings. Conversely, Yemen, Egypt, Afghanistan, and Bolivia ranked lowest in terms of health system performance.ConclusionContrary to the assumption that higher health spending guarantees improved performance, the experience of COVID-19 among high-income countries revealed mixed results. Strengthening resilience, investing in public health systems, and ensuring sustainable financial resources are crucial for enhancing health system performance.

Global health system performance rankings of the 31 countries.

Ranking of 31 countries (Out of Pocket Spending & Prepaid Private Spending Indices).

Ranking of 31 countries (Government Spending & GDP per capita Indices).

In the health index 2023, Singapore ranked first with a score of 86.9, followed by Japan and South Korea. Afghanistan had a health index score of 50.9 that year. The health index measures the extent to which people are healthy and have access to the necessary services to maintain good health, including health outcomes, health systems, illness and risk factors, and mortality rates.

In 2025, South Africa had the highest health care index in Africa with a score of 63.8, followed by Kenya with 62 points. These scores, for both countries, are considered to be reasonably high. The health care index takes into account factors such as the overall quality of the health care system, health care professionals, equipment, staff, doctors, and cost.

Ranking of 31 countries (Deaths of COVID-19 & Vaccinations of COVID-19).

The global market size of Medical Document Management System is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global Medical Document Management System Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Medical Document Management System industry. The key insights of the report:
1.The report provides key statistics on the market status of the Medical Document Management System manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of Medical Document Management System industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of Medical Document Management System Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of Medical Document Management System as well as some small players. At least 9 companies are included:
* 3M Company
* Siemens Medical Solutions
* GE Healthcare
* Allscripts Health Care Solutions
* Toshiba Medical Systems
* Cerner Corporation
For complete companies list, please ask for sample pages.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For product type segment, this report listed main product type of Medical Document Management System market
* Document Scanning Software
* Document Management Software
For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Hospitals
* Clinics
* Other

For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

Cash-and-Short-Term-Investments Time Series for IQVIA Holdings Inc. IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Objectives: To identify and map all trials in maternal health conducted in low- and middle-income countries (LMIC) over the 10-year period 2010-2019, to identify geographical and thematic trends, as well as compare to global causes of maternal death and pre-identified priority areas. Design: Systematic scoping review. Primary and secondary outcome measures: Extracted data included location, study characteristics and whether trials corresponded to causes of mortality and identified research priority topics. Results: Our search identified 7,269 articles, 874 of which were included for analysis. Between 2010 and 2019, maternal health trials conducted in LMICs more than doubled (50 to 114). Trials were conducted in 61 countries – 231 trials (26.4%) were conducted in Iran. Only 225 trials (25.7%) were aligned with a cause of maternal mortality. Within these trials, pre-existing medical conditions, embolism, obstructed labour, and sepsis were all under-represented when compared with number of maternal deaths globally. Large numbers of studies were conducted on priority topics such as labour and delivery, obstetric haemorrhage, and antenatal care. Hypertensive disorders of pregnancy, diabetes, and health systems and policy – despite being high-priority topics – had relatively few trials. Conclusion: Despite trials conducted in LMICs increasing from 2010 to 2019, there were significant gaps in geographical distribution, alignment with causes of maternal mortality, and known research priority topics. The research gaps identified provide guidance and insight for future research conducted in low-resource settings. Methods With support from an information specialist, a search strategy was devised to capture eligible studies (Supplemental Table 1). Search terms for maternal and perinatal health were derived from search strategies used by Cochrane Pregnancy and Childbirth to maintain and update their specialised register. We consulted the search filters developed by Cochrane EPOC to identify search terms relating to LMICs. The search strategy was applied to the Cochrane Central Register of Controlled Trials (CENTRAL), which retrieves records from PubMed/MEDLINE, Embase, CINAHL, ClinicalTrials.gov, WHO’s International Clinical Trials Registry Platform (ICTRP), KoreaMed, Cochrane Review Group’s Specialised Registers, and hand-searched biomedical sources. Searching CENTRAL directly had the benefit of restricting search results to trials only, keeping the volume of citations to screen to a manageable level. Trial register records from ClinicalTrials.gov and WHO ICTRP were not included in the records retrieved from CENTRAL. The search was conducted on 1 May 2020. Citation management, identification of duplicates, and screening articles for eligibility were conducted using EndNote and Covidence. Two reviewers independently screened titles and abstracts of all retrieved citations to identify those that were potentially eligible. Full texts for these articles were accessed and assessed by two independent reviewers according to the eligibility criteria. At both steps, any disagreements were resolved through discussion or consulting a third author. Data collection and analysis For each included trial we extracted information on title, author, year of publication, location where the trial was conducted (country and SDG region), unit of randomisation (individual or cluster), category of intervention, intervention level (public health, community, primary care, hospital, and health system), and category of the primary outcome(s). The intervention and outcome categories were adapted from Cochrane’s list of ‘higher-level categories for interventions and outcomes’. For trials with more than one primary outcome, we identified a single, most appropriate outcome category through discussion and consensus amongst review authors. The level of intervention was determined based on the level of the healthcare system that the trial was primarily targeting – for example, trials recruiting women at an antenatal clinic were classified as primary care level. Public health and preventative care were defined as interventions for those in the community who were well, while home; and community care was defined as interventions for those in the community who were unwell. Based on the trial’s primary objective, we tagged each trial to one of 35 maternal health topics, as well as classified them by relevance to a cause of maternal death identified by Say et al in their global systematic analysis (Box 1). Included trials were additionally categorised into global research priority topics identified by Souza et al and Chapman et al. The research priorities identified by Souza et al were ranked based on the distribution of maternal health themes across the 190 priority research questions – i.e., the theme with the most research questions was considered the highest-ranked priority topic. This mirrored the process used by Chapman et al, where research topics with the greatest representation within the 100 research questions, based on percentage, were given the highest rank. For each trial identified in our review, we used the variables extracted to classify it according to priority topics identified in Souza et al or Chapman et al, where possible (Box 1). All data were extracted by two independent reviewers, with results compared to ensure consistency and any disputes resolved through discussion or consultation with a third author. As this was a scoping review, we did not perform quality assessments on individual trials. We conducted descriptive analyses using Excel to determine frequencies of extracted variables and used line graphs to explore trends. We assessed trends over time using proportions of each variable within studies available for a given year. While we initially planned to look at trends in individual countries and interventions, many had few or no data points.

Other-Long-Term-Assets Time Series for IQVIA Holdings Inc. IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Health system performance by the clustering countries.

Total-Current-Liabilities Time Series for IQVIA Holdings Inc. IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Total-Cashflows-From-Investing-Activities Time Series for IQVIA Holdings Inc. IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Cross sectional data, all countries for the statistic Services_Value_Added_(current_Us$). Services correspond to ISIC divisions 50-99. They include value added in wholesale and retail trade (including hotels and restaurants), transport, and government, financial, professional, and personal services such as education, health care, and real estate services. Also included are imputed bank service charges and import duties. Value added is the net output of a sector after adding up all outputs and subtracting intermediate inputs. It is calculated without making deductions for depreciation of fabricated assets or depletion and degradation of natural resources. The industrial origin of value added is determined by the International Standard Industrial Classification (ISIC), revision 3. Data are in current U.S. dollars.